44 results about "Middle cerebral artery" patented technology

The invention relates to a multi-mode heart and cerebral hemodynamics monitoring method and device, and belongs to the technical field of medical equipment. According to the method, brain absorbance information and pulse wave information at the middle artery of the brain are obtained based on a near infrared spectrum technology by utilizing the relevance among the cardiac output, blood pressure, intracranial pressure and cerebral perfusion pressure of a human body, cardiac output information and cuff-free blood pressure information are obtained based on a thoracic impedance method, and physiological signals are obtained based on the two methods; and carrying out fusion processing to obtain a multi-modal signal, and further constructing a non-invasive monitoring model of non-invasive intracranial pressure, cardiac output, blood pressure and cerebral perfusion pressure, so as to realize continuous non-invasive monitoring reflecting human heart and cerebral hemodynamic parameters. According to the invention, through fusion application of multi-mode signals, the mechanism of cardio-cerebral hemodynamics interaction can be effectively disclosed, and a more effective, safer and noninvasive monitoring means is provided for clinic.

The invention discloses a construction method of a cerebral artery ischemia reperfusion model, and belongs to the technical field of animal models. Three-dimensional positioning coordinates of the middle cerebral artery are obtained through magnetic resonance scanning, the far end of the middle cerebral artery can be accurately positioned, the middle cerebral artery is induced to be blocked after irradiation by setting the blood vessel irradiation position, the rose red dosage and the laser irradiation intensity and time, blood vessel recanalization is caused along with blood impact within 4-5 hours, and finally an ischemia reperfusion model is formed. Compared with a traditional craniotomy electrocoagulation middle cerebral artery (permanent occlusion) and a traditional balloon embolism middle cerebral artery (ischemia reperfusion), the construction method has the advantages that wounds on animals are smaller, the animals are easy to survive, and compared with traditional photochemical induction which can only form infarction lesions on the surface layer of the brain, the method can induce deep brain tissue to form infarction, so that the method has the advantages of being simple and convenient to operate and the like. The method can also be expanded to other brain areas to induce deep vascular occlusion. Meanwhile, the method is also suitable for carrying out model construction on old animals, and the modeling success rate is increased.

The invention discloses application of selazinomethyl ether and a pharmaceutical composition thereof in preparation of a medicine for preventing or treating brain injury. The invention provides the application of selazine methyl ether in preparing the medicine for preventing or treating the brain injury for the first time, and selazine methyl ether has a remarkable effect in preventing or treating the brain injury, especially cerebral arterial thrombosis and the brain injury caused by hemorrhagic transformation of the cerebral arterial thrombosis. And cerebral injury caused by cerebral arterial thrombosis and hemorrhagic transformation can be obviously relieved. According to the application disclosed by the invention, the sefoazinomethyl ether has the effects of remarkably reducing the cerebral infarction area and behavioral scoring under the condition of middle cerebral artery occlusion; the selobezine methyl ether has the effects of remarkably reducing the hemorrhage area, hemorrhage score and behavioral score under acute high glucose and middle cerebral artery occlusion; the pharmaceutical composition containing selazine methyl ether can become a novel drug for preventing or treating brain injury, and can be used for treating various cerebrovascular diseases including cerebral arterial thrombosis and hemorrhagic transformation of cerebral arterial thrombosis.

The invention belongs to the technical field of biological medicines, and relates to a Rubicon permeable membrane peptide and application thereof. Specifically, the permeable membrane peptide fragment sequence is designed on the basis of an amino acid sequence of interaction of Rubi protein and Btk, and seven permeable membrane sections of arginine are connected to the tail end of the permeable membrane peptide fragment sequence through disulfide bonds. Immunofluorescence experiments prove that the peptide fragment can efficiently penetrate a platelet membrane to enter cells, and co-immunoprecipitation experiments prove that the peptide fragment has strong affinity with Btk. Platelet aggregation experiments show that the peptide fragment can significantly inhibit platelet activation under collagen stimulation. In an animal model, the peptide fragment is injected before instantaneous middle cerebral artery occlusion or reperfusion of a mouse, and ischemia-reperfusion injury can be effectively relieved. The invention provides a novel potential drug candidate for treating thrombotic diseases and ischemia-reperfusion injury.

Active medicine materials of the traditional Chinese medicine composition comprise saffron, nutmeg, clove, sandalwood and apium graveolens according to the weight ratio of 100: n1-n2: n3-n4: n5-n6: n7-n8, n1, n2, n3, n4, n5, n6, n7 and n8 are all natural numbers, n1 is larger than or equal to 100 and smaller than or equal to 300, n3 is larger than or equal to 100 and smaller than or equal to 400, n5 is larger than or equal to 200 and smaller than or equal to 800, n7 is larger than or equal to 50 and smaller than or equal to 400, and n7 is larger than or equal to 400. The composition can prevent, treat, slow down or control stroke-heart syndrome, middle cerebral artery embolism and myocardial injury of subjects, and has popularization prospects.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 neuron cells and hCMEC / D3 brain microvascular endothelial cells injured by oxygen-glucose deprivation (OGD) induction, and can resist the injury of PC12 cells induced by corticosterone (CORT) and MPP + , and effectively inhibit the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, and can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve and vascular units.

The present invention discloses the use of a polypeptide in the preparation of a drug for treating ischemic stroke, and belongs to the field of medical technology. The present invention establishes an ischemic stroke model of middle cerebral artery occlusion / reperfusion (MCAO / R) in rats, and finds that the polypeptide of the present application can significantly reduce the neurological deficit of ischemic stroke rats; in an in vitro cerebral ischemia model of human brain microvascular endothelial cells (hCMEC / D3) under a glucose-oxygen deprivation / reoxygenation-reglycosylation (OGD / R) model, it is found that the polypeptide of the present application can significantly improve the survival rate of cells.

Apparatus, systems, and methods for comparative analysis of tissue and organ scans between patients or groups of patients without sensitivity to patient-specific or scanner specific characteristics, including prediction, diagnosis, prognosis, tracking, and treatment guidance are disclosed. Blood oxygen level dependent (BOLD) fMRI is performed on a patient, and the resulting structural and functional data is preprocessed to remove artifacts and correct motion defects. A BOLD value is selected from the Vein of Galen as the maximum anatomically plausible intensity and from the Middle Cerebral Artery as the minimum anatomically plausible intensity. The maximum and minimum intensities are used to normalize the BOLD data and generate a neurovascular coupling statistical map of the brain.

The invention relates to the technical field of intracranial pressure monitoring, in particular to an intelligent non-invasive intracranial pressure monitoring and analysis system for a PICU, which integrates a multi-modal sensing array of a rigid packaging high-frequency ultrasonic probe and a flexible transcranial Doppler probe to realize conformal contact with the head and neck of a child. And synchronously acquiring an optic nerve sheath ultrasonic image and a middle cerebral artery blood flow spectrum. The system ensures data reliability through a signal quality evaluation and self-adaptive enhancement module, and a hybrid deep learning fusion core is used for estimating intracranial pressure from multi-source features with high precision and giving a confidence interval. The system is internally provided with an intracranial environment dynamic simulation and prediction engine, deduces a compensatory reserve state and predicts a future change trend based on a volume-pressure model, and finally outputs a personalized Pareto optimal intervention strategy sequence through a decision module driven by reinforcement learning. According to the PICU intracranial pressure management system and method, full-process support from non-invasive monitoring and accurate prediction to intelligent decision making is achieved, and the technical level and clinical efficacy of PICU intracranial pressure management are remarkably improved.

The invention discloses a construction and evaluation method of an acute ischemic cerebral apoplexy phlegm and blood stasis toxin intermingling syndrome animal model, which comprises the following steps: adaptively feeding rats for 1 week, and feeding the rats with high-fat feed; from the 26th day, 20 mg / kg carrageenan (Ca) is subjected to intraperitoneal injection for 3 days continuously; the rat cerebral ischemia / reperfusion model is prepared by adopting an MCAO / R suture suppository method when the rat is raised to the 29-day morning, and the method specifically comprises the following steps: fasting 12 hours before modeling, and supplying a small amount of water; injecting 3% pentobarbital (2ml / kg) into the intraperitoneal cavity of the rat for anesthesia; fixing the supine position of the rat after successful anesthesia, exposing and separating the right common carotid artery; cutting a V-shaped incision at the separated common carotid artery, inserting a suture into the internal carotid artery from the V-shaped incision, and advancing until the middle cerebral artery is blocked and ligated; when the suture is inserted into the middle cerebral artery, the time is 0; suturing the skin after an operation, and exposing the tail end of the tying line in vitro; and after 1.5 hours, the tying line is pulled out, and cerebral ischemia reperfusion is simulated.

The invention belongs to the technical field of animal model construction, and relates to a method for establishing an oriental vole permanent cerebral ischemia model. A nylon wire bolt with the head end diameter of 0.22 + / -0.02 mm is used, a mark is made at the position, 1.5 cm away from the head end, of the wire bolt, the wire bolt is inserted through a neck artery wound of the eastern vole and enters the middle artery of the vole brain through the internal carotid artery, and therefore the front end of the middle artery is blocked, and the vole permanent cerebral ischemia model is completed. The permanent cerebral ischemia model of the oriental vole is successfully established. The model has the characteristics of stable infarction volume, low death rate and uniform cerebral infarction range, and provides a more reliable and effective animal model for stroke related research.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The invention belongs to the technical field of medicines, and particularly relates to application of lycium barbarum glycopeptide in preparation of a medicine for preventing or treating ischemic encephalopathy. Specifically, the invention relates to application of lycium barbarum glycopeptide in preparation of drugs for preventing or treating cerebral arterial thrombosis. Pharmacological experiments show that the lycium barbarum glycopeptide has an obvious treatment effect on dyskinesia and neurological impairment of focal ischemic stroke model rats caused by middle cerebral artery ischemia reperfusion; the compound also has a remarkable improvement effect on learning and memory cognitive impairment of the model rat, so that the compound can be used for preparing medicines for preventing or treating related ischemic encephalopathy.

The invention discloses an improved and simplified modeling method of a rat middle cerebral artery embolism ischemia model and an auxiliary precise thrombus pushing device.According to the modeling method, standardized thrombus embolism is prepared through an in-vitro step, and the modeling method comprises the steps that blood is incubated in a PE-50 catheter at the specific temperature for the specific time to form initial thrombus; the diameter is accurately controlled to be smaller than 0.14 mm through reciprocating push-pull and negative pressure folding suction of a PE-10 catheter; then, loading the emboli by using a normalized vascular catheter with a 20mm pre-mark; during modeling, the catheter is inserted to a preset depth through an external carotid artery, and the thrombus is pushed into a target blood vessel at a constant speed of 10-20 [mu] L / min by means of an auxiliary precise thrombus pushing device. The core problems of poor thrombus quality and low model stability and repeatability of a traditional method are effectively solved by optimizing the whole process of thrombus preparation, catheter specification, pushing rate and verification standard in combination with a special device, the success rate of the model can reach 90% or above, and an efficient and reliable experimental tool is provided for cerebral apoplexy research.

Conventionally, the arterial input function is determined by administering a contrast agent and measuring the responsive magnetic signal in a reference voxel located in a large artery such as the middle cerebral artery. By instead measuring the signal in a voxel of the choroid plexus, a more accurate profile for the arterial input function may be obtained. The metabolic activity in the choroid plexus is negligible, which provides greater certainty for signal sampling.

Application of total flavonoid extract of Ziziphora clinopodioides Lam. in the preparation of drugs for treating cerebral ischemia-reperfusion injury. The present invention belongs to the field of cerebrovascular diseases, and particularly relates to the application of total flavonoid extract of Ziziphora clinopodioides Lam. (ZCF) in the preparation of drugs for treating cerebral ischemia-reperfusion injury. The present invention has studied the effects of different doses of ZCF against cerebral ischemia-reperfusion injury. The research shows that ZCF has a significant therapeutic effect on Sprague-Dawley rats with a middle cerebral artery occlusion-reperfusion (MCAO / R) model prepared by the suture method, significantly reduces the cerebral infarction area (Figure 1), reduces the blood-brain barrier permeability, and can effectively improve cognitive and motor dysfunction. The present invention also provides a drug that effectively resists cerebral ischemia-reperfusion injury, and can provide a reliable experimental basis and theoretical basis for the development of drugs for treating cerebral ischemia-reperfusion injury using Ziziphora clinopodioides Lam.

The invention discloses application of a compound high spot-nourishing tablet in preparation of a medicine for treating cerebral ischemia-reperfusion injury. A rat cerebral ischemia reperfusion injury model is established through middle cerebral artery embolism, and serum, pathology and infarction areas of rats are observed and detected. Results show that the neurological score of the model group ZeaLonga is significantly increased, pathological changes are large, proinflammatory factors TNF-alpha, IL-6 and IL-1beta are significantly increased, oxidation promoting MDA is significantly increased, and antioxidant SOD expression is significantly increased. And compared with a model group, the weight, the neurological score and the survival rate are obviously improved. The results of HE staining, TTC staining and TUNEL staining show that the nerve cell morphology, arrangement, infarct area and cell apoptosis condition of each administration group are obviously improved. The application provided by the invention can improve the behavior of rats, reduce the infarct area, protect nerve cells and reduce the apoptosis of ischemic regions; by reducing inflammation and oxidation in rat brain tissues, damage of inflammation and oxidative stress to the rat brain tissues is reduced.

The application discloses a middle cerebral artery high-density sign identification method, device, equipment and storage medium. In the identification method, first, the middle cerebral artery region of a brain CT plain scan image is extracted to obtain a region extraction image; then, according to a blood vessel enhanced image corresponding to the region extraction image, position information of a middle cerebral artery high-density sign candidate box is obtained; then, texture features are obtained according to the region extraction image and the position information, and shape features are obtained according to the blood vessel enhanced image and the position information; finally, a middle cerebral artery high-density sign identification result is obtained according to the texture features and the shape features. The application can realize accurate and reliable identification of HMCAS in a complex brain lesion environment, and has strong adaptability to scanning equipment and individual imaging differences.

The invention belongs to the technical field of medicines, and discloses application of a magnolol nitrone derivative HL-3 in preparation of medicines for preventing or treating cerebral infarction. The HL-3 shows a remarkable treatment effect in both in-vitro and in-vivo experiments. In an in-vitro experiment, the HL-3 can effectively relieve damage caused by oxygen glucose deprivation / reoxygenation (OGDR) of SK-N-SH cells under the concentration of 10 micromoles (mu M), the cell survival rate is remarkably increased, and it is indicated that the HL-3 has a high neuroprotective effect. In an integral animal experiment, the HL-3 shows an obvious treatment effect on transient middle cerebral artery occlusion (tMCAO) and permanent middle cerebral artery occlusion (pMCAO) models of SD (Sprague Dawley) rats under the dosage of 1mg / kg and 10mg / kg. Specifically, the cerebral infarction volume is reduced, and the neurological function score is improved. The results show that the HL-3 is effective in various models, has wide applicability and remarkable treatment potential, and provides a new and effective drug choice for cerebral infarction treatment.

A use of a CD146+ mesenchymal stem cell in preparation of a drug for preventing and / or treating cerebral apoplexy. The drug can significantly alleviate neurological impairment symptoms of a middle cerebral artery occlusion (MCAO) model of a mouse, improves the exercise behavior capability, and decreases the degree of cerebral infarction. The umbilical cord mesenchymal stem cell subpopulation of a specific surface marker has been confirmed for the first time to have an effect in treatment of cerebral apoplexy, has broad prospects in the treatment of cerebral apoplexy, and has high clinical value.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for preventing or treating ischemic encephalopathy and application thereof, and the pharmaceutical composition comprises ginsenoside Rg1, ruscogenin and schizandrin. In an in-vitro oxygen-sugar deficiency / reperfusion induced bEnd.3 cell injury model, compared with a corresponding monomer component, the pharmaceutical composition disclosed by the invention can obviously recover the cell activity. In an in-vivo rat middle cerebral artery obstruction reperfusion model, the pharmaceutical composition disclosed by the invention can be used for remarkably reducing the cerebral infarction volume, improving the neural behavior function and recovering cerebral blood flow in an ischemic area. Meanwhile, toxicity is not shown in the continuous administration period. The results show that the pharmaceutical composition has an application prospect in treatment of cerebral arterial thrombosis, especially in improvement of ischemia reperfusion prognosis by restoring blood flow.

This invention relates to a prediction system, electronic device, and readable storage medium for sepsis-associated encephalopathy (SEEE). The system includes: a data acquisition module for acquiring measurements of neuron-specific enolase levels, transcranial ultrasound-measured peak systolic velocity of the left middle cerebral artery, and an APACHE II score reflecting disease severity; and a SEEE prediction module for obtaining the risk probability of sepsis-associated encephalopathy in sepsis patients using a pre-built and trained prediction model based on the acquired neuron-specific enolase levels, transcranial ultrasound-measured peak systolic velocity of the left middle cerebral artery, and APACHE II score reflecting disease severity. Compared with existing technologies, this invention can predict the risk of sepsis-associated encephalopathy in patients at an early stage and has good accuracy, simplicity, and practicality.

The application discloses a tetrazole derivative, which has a structure shown in a general formula I. The application also discloses a composition containing the tetrazole derivative and application of the tetrazole derivative in preparation of a drug for preventing and resisting stroke. The inventors of the application have confirmed through multiple experiments that the compound has obvious inhibiting effect on ADP-induced platelet aggregation activity, outstanding damage protection effect on OGD / R fetal rat primary cortical neuron cells and neuron-like cells induced and differentiated from neuroblastoma cells (N2A), good anti-stroke efficacy on an animal model of focal cerebral ischemia constructed by a line plug method for temporarily blocking a middle cerebral artery and good rat oral pharmacokinetic properties. Therefore, the compound can be applied to a drug for treating and preventing stroke as a neuroprotective agent.

The invention belongs to the technical field of biological medicine, and particularly relates to application of phthalide isoquinoline alkaloid in corydalis amabilis to preparation of a medicine for resisting cerebral ischemia. According to the application disclosed by the invention, corydalis amabilis with definite anti-cerebral ischemia activity is taken as a research object, and the anti-cerebral ischemia activity target P21 protein activating enzyme 2 of the corydalis amabilis is obtained and identified from ischemic brain tissues of middle cerebral artery occlusion (MCAO) rats by using a molecular target'hooking 'technology based on thermal proteomics. Then, the inventor detects the binding force of a monomeric compound and a target protein in corydalis amabilis by using a surface plasmon resonance technology, and finally screens out a key substance phthalide isoquinoline alkaloid, which exerts the anti-cerebral ischemia activity, in corydalis amabilis.

An embodiment of this specification discloses a neural network model for classification and its application, belonging to the fields of medical imaging and computer technology. The model includes: an input module, a first module, a second module, and an output module; wherein, the input module is used to receive the image data to be processed; the first module is used to extract the first feature of the image data to be processed; the second module is used to extract the second feature of the image data to be processed; the output module is used to perform classification based on the first feature and the second feature of the image data to be processed, and obtain the classification result of the image data to be processed. The input module adopts the neural network model provided by the embodiment of this specification and can be applied to the imaging diagnosis of non-acute occlusion of the middle cerebral artery, providing a reference basis for clinical treatment.

The invention relates to the technical field of experimental animal cerebral ischemia model construction, in particular to a cerebral ischemia model percutaneous puncture suture introduction method and a cerebral ischemia model percutaneous puncture suture introduction device, and the method comprises the following steps: percutaneous puncture of common carotid artery by a superfine puncture needle, withdrawal of the puncture needle after feeding into a micro catheter sheath through a needle cavity, and compression hemostasis by an external pressure type micro air bag ring. The suture is pushed to the starting section of the middle cerebral artery through the micro catheter sheath to complete embolism, the suture is withdrawn during reperfusion, air bag hemostasis is carried out again, and the device comprises a superfine puncture needle, the coaxial micro catheter sheath, a suture pushing core wire and an external pressure type micro air bag ring which form a three-layer nested structure, and the superfine puncture needle, the coaxial micro catheter sheath, the suture pushing core wire and the external pressure type micro air bag ring form a three-layer nested structure. The integrity of the blood vessels and the smoothness of the blood flow are completely retained after operation.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine extract as well as a preparation method and application thereof, and the traditional Chinese medicine extract is extracted from a prescription comprising ligusticum wallichii and gastrodia elata. The traditional Chinese medicine extract contains 60 wt.%-70 wt.% of neutral sugar, the optimal ratio of ligusticum wallichii to gastrodia elata is selected, and the extract obtained from the ligusticum wallichii and gastrodia elata can exert specific pharmacodynamic activity and has a good curative effect on treatment of migraine and / or middle cerebral artery occlusion syndrome.

The invention discloses application of RNF125 as a new target in relieving cerebral ischemia reperfusion injury, and relates to the technical field of biological medicine. Comprising one or more of the following items: application to reduction of cerebral infarction volume after middle cerebral artery embolism based on interference RNF125; based on RNF125 gene knock-down, the invention is applied to improvement of behavioral function defects after middle cerebral artery embolism; based on the interference RNF125, neuronal loss is reduced after middle cerebral artery embolism, and brain tissue damage is relieved; based on interference RNF125, the invention is applied to relieving inflammatory response after middle cerebral artery embolism. The application focuses on RNF125 as a new therapeutic target, and shows a remarkable effect in the aspect of relieving cerebral ischemia-reperfusion injury; by interfering with the expression of RNF125, the cerebral infarction volume in a mouse model can be effectively reduced, the neurological function can be improved, and brain tissue damage can be relieved.

The present invention relates to a pharmaceutical composition for preventing or treating stroke, comprising a pressed extract, a solvent extract or a fraction of a solvent extract of Juglans mandshurica fruit. The Juglans mandshurica fruit exhibits a protective effect on brain tissue (brain cells) against ischemic brain tissue damage induced by middle cerebral artery occlusion and reduces infarction, and thus can be usefully used for a pharmaceutical composition or health functional food for preventing, ameliorating or treating stroke.

The purpose of the present invention is to provide a method and a system for detecting an MES from a Doppler ultrasound signal by using artificial intelligence. The purpose of the present invention is to enhance detection efficiency by rapidly scanning a wide area of a cerebral blood vessel by using a two-dimensional array ultrasonic transducer, to implement automatic identification and accurate positioning of a middle cerebral artery through an artificial intelligence algorithm so as to minimize user dependence, and to construct a continuous and automated blood flow monitoring system to enable precise analysis of a blood flow state in real time to achieve effective detection of an MES.